MetaCap

Amphastar Pharmaceuticals (AMPH) vs OPKO Health (OPK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OPKO Health (OPK) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 18.9% versus a gain of 8.6%. Over five years, AMPH leads with a +41.9% price change compared with -62.0% for OPK. Amphastar Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.17 billion), about 1.0 times the size.

Amphastar Pharmaceuticals converts more of its revenue into profit, with a net margin of 13.6% versus -37.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%OPK+18.94%
+38%-1%-39%
Nov 21, 20251 yearNov 20, 2026
AMPH+37.74%OPK-63.91%
+221%+63%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus OPK key metrics
MetricAMPHOPK
Share price$28.25$1.57
Market cap$1.20B$1.17B
1-day change+0.50%-2.48%
YTD return+5.49%+24.60%
1-year return+8.61%+18.94%
5-year return+41.89%-61.99%
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-0.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M$606.88M
Revenue growth (YoY)-1.65%-14.90%
Net income (latest FY)$98.09M$-225.68M
Gross margin49.46%33.93%
Operating margin19.50%-19.35%
Net margin13.63%-37.19%
52-week high$31.00$1.86
52-week low$16.65$0.98
Distance from 52-week high-8.87%-15.59%
Analyst consensusholdbuy
Avg. price target upside-13.27%+164.33%
Average volume475.35K3.83M
Shares outstanding42.65M742.51M
Employees1,9762,275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OPK has outperformed AMPH by 10.3 percentage points over the past year.
  • Amphastar Pharmaceuticals is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -37.2 cents for OPKO Health.
  • Amphastar Pharmaceuticals grew revenue faster in its latest fiscal year (-1.65% vs -14.90%).

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About OPKO Health

OPK stock →

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees

AMPH vs OPK FAQ

Which is bigger, Amphastar Pharmaceuticals or OPKO Health?

Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.20B compared with $1.17B for OPKO Health (OPK).

Which stock has performed better over the past year, AMPH or OPK?

OPK returned +18.94% over the past 12 months, compared with +8.61% for AMPH (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and OPKO Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons